---
title: "BrightSpring Health Services - Unit | 8-K: FY2025 Q1 Revenue: USD 2.878 B"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238558530.md"
datetime: "2025-05-02T10:06:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238558530.md)
  - [en](https://longbridge.com/en/news/238558530.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238558530.md)
generator: "portal-rs"
---

# BrightSpring Health Services - Unit | 8-K: FY2025 Q1 Revenue: USD 2.878 B

Revenue: As of FY2025 Q1, the actual value is USD 2.878 B.

EPS: As of FY2025 Q1, the actual value is USD 0.14.

EBIT: As of FY2025 Q1, the actual value is USD 91.57 M.

### Segment Revenue

-   **Pharmacy Solutions Revenue**: $2,532 million, up 28% from $1,977 million in the first quarter of 2024.
-   **Provider Services Revenue**: $346 million, up 12% from $309 million in the first quarter of 2024.

### Operational Metrics

-   **Net Income from Continuing Operations**: $9.2 million, compared to a Net Loss of $56.0 million in the first quarter of 2024.
-   **Gross Profit**: $338 million, up 15.7% from $292 million in the first quarter of 2024.
-   **Operating Income**: $50.7 million, compared to an Operating Loss of - $15.3 million in the first quarter of 2024.

### Cash Flow

-   **Net Cash Provided by Operating Activities**: $101.6 million, compared to - $78.9 million in the first quarter of 2024.

### Unique Metrics

-   **Adjusted EBITDA**: $131 million, up 28.2% from $102 million in the first quarter of 2024.

### Outlook / Guidance

BrightSpring Health Services has increased its full-year 2025 guidance, projecting net revenue between $12,000 million and $12,500 million, and Adjusted EBITDA between $570 million and $585 million. The Pharmacy Segment Revenue is expected to grow between 20.5% and 25.7%, while the Provider Segment Revenue is anticipated to increase between 10.0% and 13.8%.

### Related Stocks

- [BTSGU.US](https://longbridge.com/en/quote/BTSGU.US.md)

## Related News & Research

- [PepsiCo Hasn't Been This Cheap Relative to Free Cash Flow in 10 Years. Here's Why That's the Signal to Buy.](https://longbridge.com/en/news/298135920.md)
- [Does IMAAVY’s Approval and Ongoing Talc Verdict Meaningfully Shift the Bull Case for Johnson & Johnson (JNJ)?](https://longbridge.com/en/news/298140186.md)
- [Coca-Cola: Buy, Sell, or Hold After Its Recent Run?](https://longbridge.com/en/news/298137224.md)
- [Docusign’s Broad Risk Disclosures Signal Heightened Uncertainty and Higher Investor Risk Premiums](https://longbridge.com/en/news/298124541.md)
- [Does Instacart’s New Exclusivity And Category Expansions Reshape The Bull Case For Maplebear (CART)?](https://longbridge.com/en/news/298119807.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**